Identification

Name
Nitroprusside
Accession Number
DB00325  (APRD01143)
Type
Small Molecule
Groups
Approved
Description

Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency. [Wikipedia]

Structure
Thumb
Synonyms
  • [Fe(CN)5(NO)](2-)
  • Nitroferricyanide
Product Ingredients
IngredientUNIICASInChI Key
Sodium nitroprussideEAO03PE1TC13755-38-9SPBWMYPZWNFWES-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NipridePowder, for solution50 mgIntravenousHospira, Inc.1975-12-312011-08-05Canada
NiprideSolution25 mgIntravenousPfizer2011-05-17Not applicableCanada
Nipride RtuInjection, solution.5 mg/mLIntravenousExela Pharma Sciences, Llc.2017-03-20Not applicableUs
Sodium Nitroprusside for InjectionSolution25 mgIntravenousSterimax IncNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NitropressInjection, solution, concentrate50 mg/2mLIntravenousHospira, Inc.1988-08-012017-06-24Us
NitropressInjection, solution, concentrate50 mg/2mLIntravenousValeant Pharmaceuticals North America2013-12-01Not applicableUs
NitropressInjection, solution, concentrate50 mg/2mLIntravenousMarathon Pharmaceuticals2013-12-012016-05-31Us
Sodium NitroprussideInjection, solution, concentrate50 mg/2mLIntravenousAkorn2017-05-04Not applicableUs
Sodium NitroprussideInjection, solution, concentrate25 mg/mLIntravenousSagent Pharmaceuticals2016-10-06Not applicableUs
Sodium NitroprussideInjection25 mg/mLIntravenousNexus Pharmaceuticals Inc2017-05-29Not applicableUs
Categories
UNII
169D1260KM
CAS number
15078-28-1
Weight
Average: 215.938
Monoisotopic: 215.948300785
Chemical Formula
C5FeN6O
InChI Key
ASPOIVQEUUCDQT-UHFFFAOYSA-N
InChI
InChI=1S/5CN.Fe.NO/c5*1-2;;1-2/q;;;;;2*-1
IUPAC Name
pentacyano(nitroso)irondiuide
SMILES
O=N[Fe--](C#N)(C#N)(C#N)(C#N)C#N

Pharmacology

Indication

For immediate reduction of blood pressure of patients in hypertensive crises, reduce bleeding during surgery, and for the treatment of acute congestive heart failure

Structured Indications
Pharmacodynamics

Nitroprusside a powerful vasodilator relaxes the vascular smooth muscle and produce consequent dilatation of peripheral arteries and veins. Other smooth muscle (e.g., uterus, duodenum) is not affected. Sodium nitroprusside is more active on veins than on arteries.

Mechanism of action

One molecule of sodium nitroprusside is metabolized by combination with hemoglobin to produce one molecule of cyanmethemoglobin and four CN- ions; methemoglobin, obtained from hemoglobin, can sequester cyanide as cyanmethemoglobin; thiosulfate reacts with cyanide to produce thiocyanate; thiocyanate is eliminated in the urine; cyanide not otherwise removed binds to cytochromes. Cyanide ion is normally found in serum; it is derived from dietary substrates and from tobacco smoke. Cyanide binds avidly (but reversibly) to ferric ion (Fe+++), most body stores of which are found in erythrocyte methemoglobin (metHgb) and in mitochondrial cytochromes. When CN is infused or generated within the bloodstream, essentially all of it is bound to methemoglobin until intraerythrocytic methemoglobin has been saturated. Once activated to NO, it activates guanylate cyclase in vascular smooth muscle and increases intracellular production of cGMP. cGMP stimulates calcium movement from the cytoplasm to the endoplasmic reticulum and reduces calcium available to bind with calmodulin. This eventually leads to vascular smooth muscle relaxation and vessel dilatation.

TargetActionsOrganism
AAtrial natriuretic peptide receptor 1
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Metabolized by reaction with hemoglobin to produce cyanmethemoglobin and cynide ions

Route of elimination

One molecule of sodium nitroprusside is metabolized by combination with hemoglobin to produce one molecule of cyanmethemoglobin and four CN¯ ions, thiosulfate reacts with cyanide to produce thiocyanate, thiocyanate is eliminated in the urine.

Half life

Approximately 2 minutes

Clearance
Not Available
Toxicity

Overdosage of nitroprusside can be manifested as excessive hypotension or cyanide toxicity or as thiocyanate toxicity. The acute intravenous mean lethal doses (LD50) of nitroprusside in rabbits, dogs, mice, and rats are 2.8, 5.0, 8.4, and 11.2 mg/kg, respectively.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nitroprusside.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Acebutolol.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroprusside.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Nitroprusside.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Aliskiren.Approved, Investigational
AlprenololNitroprusside may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanNitroprusside may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineNitroprusside may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nitroprusside.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Nitroprusside.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Nitroprusside.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitroprusside.Approved, Investigational
AmrinoneAmrinone may increase the hypotensive activities of Nitroprusside.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Nitroprusside.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Nitroprusside.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nitroprusside.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nitroprusside.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Atenolol.Approved
AzelnidipineAzelnidipine may increase the hypotensive activities of Nitroprusside.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Azilsartan medoxomil.Approved
AzimilideAzimilide may increase the hypotensive activities of Nitroprusside.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Nitroprusside.Experimental
BarbitalBarbital may increase the hypotensive activities of Nitroprusside.Illicit
BarnidipineBarnidipine may increase the hypotensive activities of Nitroprusside.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Benazepril.Approved, Investigational
BencyclaneBencyclane may increase the hypotensive activities of Nitroprusside.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bendroflumethiazide.Approved
BenidipineBenidipine may increase the hypotensive activities of Nitroprusside.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nitroprusside.Withdrawn
BepridilBepridil may increase the hypotensive activities of Nitroprusside.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nitroprusside.Approved
BethanidineBethanidine may increase the hypotensive activities of Nitroprusside.Approved
BietaserpineNitroprusside may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostNitroprusside may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Nitroprusside.Approved, Investigational
BosentanNitroprusside may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Nitroprusside may increase the hypotensive activities of BQ-123.Investigational
BretyliumThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Nitroprusside.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Nitroprusside.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nitroprusside.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitroprusside.Approved, Investigational
BupranololNitroprusside may increase the hypotensive activities of Bupranolol.Approved
CadralazineNitroprusside may increase the hypotensive activities of Cadralazine.Experimental
CafedrineNitroprusside may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Candesartan.Approved
CandoxatrilNitroprusside may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nitroprusside.Approved
CarboxyamidotriazoleCarboxyamidotriazole may increase the hypotensive activities of Nitroprusside.Investigational
CaroverineCaroverine may increase the hypotensive activities of Nitroprusside.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Nitroprusside.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Carvedilol.Approved, Investigational
CeliprololNitroprusside may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitroprusside.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nitroprusside.Approved
CicletanineNitroprusside may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Cilazapril.Approved
CilnidipineCilnidipine may increase the hypotensive activities of Nitroprusside.Approved
CinnarizineCinnarizine may increase the hypotensive activities of Nitroprusside.Approved
ClevidipineClevidipine may increase the hypotensive activities of Nitroprusside.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Nitroprusside.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nitroprusside.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Clonidine.Approved
CloranololNitroprusside may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Nitroprusside.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nitroprusside.Approved, Investigational
CryptenamineNitroprusside may increase the hypotensive activities of Cryptenamine.Approved
CyclopenthiazideNitroprusside may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideNitroprusside may increase the hypotensive activities of Cyclothiazide.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dapagliflozin.Approved
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Nitroprusside.Approved, Investigational
DarodipineDarodipine may increase the hypotensive activities of Nitroprusside.Experimental
DebrisoquinNitroprusside may increase the hypotensive activities of Debrisoquin.Approved
DelaprilNitroprusside may increase the hypotensive activities of Delapril.Experimental
DeserpidineNitroprusside may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nitroprusside.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nitroprusside.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Diclofenamide.Approved
diethylnorspermineNitroprusside may increase the hypotensive activities of diethylnorspermine.Investigational
DihydralazineNitroprusside may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Nitroprusside.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dipyridamole.Approved
DorzolamideNitroprusside may increase the hypotensive activities of Dorzolamide.Approved
DotarizineDotarizine may increase the hypotensive activities of Nitroprusside.Investigational
DoxazosinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Doxazosin.Approved
DuloxetineNitroprusside may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Nitroprusside.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Enalapril.Approved, Vet Approved
EnalaprilatNitroprusside may increase the hypotensive activities of Enalaprilat.Approved
EndralazineNitroprusside may increase the hypotensive activities of Endralazine.Experimental
EpanololNitroprusside may increase the hypotensive activities of Epanolol.Experimental
EperisoneEperisone may increase the hypotensive activities of Nitroprusside.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Eplerenone.Approved
EpoprostenolNitroprusside may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nitroprusside.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Etacrynic acid.Approved
FelodipineFelodipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
FendilineFendiline may increase the hypotensive activities of Nitroprusside.Withdrawn
FenoldopamNitroprusside may increase the hypotensive activities of Fenoldopam.Approved
Ferulic acidNitroprusside may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nitroprusside.Approved
FlunarizineFlunarizine may increase the hypotensive activities of Nitroprusside.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Nitroprusside.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Furosemide.Approved, Vet Approved
GabapentinGabapentin may increase the hypotensive activities of Nitroprusside.Approved, Investigational
GallopamilGallopamil may increase the hypotensive activities of Nitroprusside.Investigational
GuanabenzNitroprusside may increase the hypotensive activities of Guanabenz.Approved
GuanadrelNitroprusside may increase the hypotensive activities of Guanadrel.Approved
GuanazodineNitroprusside may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineNitroprusside may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Guanfacine.Approved, Investigational
GuanoclorNitroprusside may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzNitroprusside may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanNitroprusside may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Nitroprusside.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Nitroprusside.Experimental
HexamethoniumNitroprusside may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Nitroprusside.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Nitroprusside.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideNitroprusside may increase the hypotensive activities of Hydroflumethiazide.Approved
IloprostIloprost may increase the hypotensive activities of Nitroprusside.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Nitroprusside.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nitroprusside.Approved
IndapamideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Indapamide.Approved
IndenololNitroprusside may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminNitroprusside may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Nitroprusside.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Nitroprusside.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nitroprusside.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nitroprusside.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Nitroprusside.Approved
KetanserinNitroprusside may increase the hypotensive activities of Ketanserin.Investigational
LabetalolThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Labetalol.Approved
LacidipineLacidipine may increase the hypotensive activities of Nitroprusside.Approved
LamotrigineLamotrigine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
LatanoprostNitroprusside may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nitroprusside.Approved
LevodopaNitroprusside may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Nitroprusside.Approved, Investigational
LidoflazineLidoflazine may increase the hypotensive activities of Nitroprusside.Experimental
LinsidomineNitroprusside may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Lisinopril.Approved, Investigational
LofexidineNitroprusside may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Losartan.Approved
MacitentanNitroprusside may increase the hypotensive activities of Macitentan.Approved
Magnesium SulfateMagnesium Sulfate may increase the hypotensive activities of Nitroprusside.Approved, Vet Approved
ManidipineManidipine may increase the hypotensive activities of Nitroprusside.Approved
MannitolThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Nitroprusside.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Mecamylamine.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Nitroprusside.Approved
MethoserpidineNitroprusside may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitroprusside.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nitroprusside.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nitroprusside.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nitroprusside.Approved
MetipranololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nitroprusside.Approved, Investigational
MetyrosineNitroprusside may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Nitroprusside.Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Nitroprusside.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Minoxidil.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Nitroprusside.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Nitroprusside.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Nitroprusside.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nitroprusside.Approved, Investigational
MoxonidineNitroprusside may increase the hypotensive activities of Moxonidine.Approved
MuzolimineNitroprusside may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nitroprusside.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Nadolol.Approved
NaftopidilNaftopidil may increase the hypotensive activities of Nitroprusside.Investigational
NebivololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Nitroprusside.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Nitroprusside.Approved
NicorandilNicorandil may increase the hypotensive activities of Nitroprusside.Approved
NifedipineNifedipine may increase the hypotensive activities of Nitroprusside.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Nitroprusside.Experimental
NiludipineNiludipine may increase the hypotensive activities of Nitroprusside.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Nitroprusside.Approved
NimesulideNimesulide may increase the hypotensive activities of Nitroprusside.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Nitroprusside.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Nitroprusside.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Nitroprusside.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Nitroprusside.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Nitroglycerin.Approved, Investigational
ObinutuzumabNitroprusside may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Nitroprusside.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nitroprusside.Approved, Investigational
OmapatrilatNitroprusside may increase the hypotensive activities of Omapatrilat.Investigational
OtiloniumOtilonium may increase the hypotensive activities of Nitroprusside.Experimental
OxprenololNitroprusside may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nitroprusside.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Nitroprusside.Approved
PenbutololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Nitroprusside.Approved, Vet Approved
PentoliniumNitroprusside may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nitroprusside.Approved, Investigational
PerhexilinePerhexiline may increase the hypotensive activities of Nitroprusside.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Nitroprusside.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Nitroprusside.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Nitroprusside.Approved
PhenoxybenzamineNitroprusside may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nitroprusside.Withdrawn
PhentolamineNitroprusside may increase the hypotensive activities of Phentolamine.Approved
PinacidilNitroprusside may increase the hypotensive activities of Pinacidil.Withdrawn
PinaveriumPinaverium may increase the hypotensive activities of Nitroprusside.Approved
PindololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nitroprusside.Approved
PirlindolePirlindole may increase the hypotensive activities of Nitroprusside.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Nitroprusside.Withdrawn
PolythiazideNitroprusside may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nitroprusside.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Prazosin.Approved
PregabalinPregabalin may increase the hypotensive activities of Nitroprusside.Approved, Illicit, Investigational
PrenylaminePrenylamine may increase the hypotensive activities of Nitroprusside.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Prilocaine.Approved
PrimidonePrimidone may increase the hypotensive activities of Nitroprusside.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Nitroprusside.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Propranolol.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Nitroprusside.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nitroprusside.Approved
RasagilineRasagiline may increase the hypotensive activities of Nitroprusside.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nitroprusside.Approved
RemikirenNitroprusside may increase the hypotensive activities of Remikiren.Approved
RescinnamineNitroprusside may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nitroprusside.Approved
RilmenidineNitroprusside may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Riociguat.Approved
RisedronateRisedronate may increase the hypotensive activities of Nitroprusside.Approved, Investigational
RisperidoneNitroprusside may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabNitroprusside may increase the hypotensive activities of Rituximab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Nitroprusside.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nitroprusside.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Nitroprusside.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Nitroprusside.Approved
SafrazineSafrazine may increase the hypotensive activities of Nitroprusside.Withdrawn
SaprisartanNitroprusside may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Nitroprusside.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Nitroprusside.Approved, Investigational, Vet Approved
SelexipagNitroprusside may increase the hypotensive activities of Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nitroprusside.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Nitroprusside.Approved, Investigational
SitaxentanNitroprusside may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Sotalol.Approved
SpiraprilNitroprusside may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Nitroprusside.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nitroprusside.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Nitroprusside.Approved, Investigational
TalinololNitroprusside may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Nitroprusside.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Telmisartan.Approved, Investigational
TemocaprilNitroprusside may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Terazosin.Approved
TerlipressinNitroprusside may increase the hypotensive activities of Terlipressin.Approved, Investigational
TerodilineTerodiline may increase the hypotensive activities of Nitroprusside.Experimental
TetrahydropalmatineTetrahydropalmatine may increase the hypotensive activities of Nitroprusside.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nitroprusside.Approved, Investigational, Withdrawn
TheodrenalineNitroprusside may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Nitroprusside.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Nitroprusside.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nitroprusside.Withdrawn
TiboloneNitroprusside may increase the hypotensive activities of Tibolone.Approved
TicrynafenNitroprusside may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Tizanidine.Approved
TolazolineNitroprusside may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nitroprusside.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may increase the hypotensive activities of Nitroprusside.Approved
TolonidineNitroprusside may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Nitroprusside.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nitroprusside.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Trandolapril.Approved
TranilastTranilast may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nitroprusside.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Nitroprusside.Approved
TravoprostNitroprusside may increase the hypotensive activities of Travoprost.Approved
TreprostinilNitroprusside may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Nitroprusside.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Triamterene.Approved
TrichlormethiazideNitroprusside may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinNitroprusside may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanNitroprusside may increase the hypotensive activities of Trimethaphan.Approved
UdenafilUdenafil may increase the antihypertensive activities of Nitroprusside.Approved, Investigational
UnoprostoneNitroprusside may increase the hypotensive activities of Unoprostone.Approved
UrapidilNitroprusside may increase the hypotensive activities of Urapidil.Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nitroprusside.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Nitroprusside.Approved
VerapamilVerapamil may increase the hypotensive activities of Nitroprusside.Approved
VincamineNitroprusside may increase the hypotensive activities of Vincamine.Experimental
VinpocetineVinpocetine may increase the hypotensive activities of Nitroprusside.Investigational
XipamideNitroprusside may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Nitroprusside.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Nitroprusside.Approved, Vet Approved
ZiconotideZiconotide may increase the hypotensive activities of Nitroprusside.Approved
ZofenoprilNitroprusside may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
Human Metabolome Database
HMDB14470
KEGG Compound
C07269
PubChem Compound
11963622
PubChem Substance
46508965
ChemSpider
21607452
BindingDB
50377921
ChEBI
7596
ChEMBL
CHEMBL2097081
Therapeutic Targets Database
DNC001351
PharmGKB
PA451406
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Nitroprusside
ATC Codes
C02DD01 — Nitroprusside
AHFS Codes
  • 24:08.20
PDB Entries
Not Available
FDA label
Not Available
MSDS
Download (79 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAging1
1CompletedBasic ScienceSarcopenia2
1CompletedBasic ScienceSchizophrenic Disorders1
1TerminatedOtherInflammatory Reaction1
1Unknown StatusTreatmentAcute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) / Arterial hypoxia / Respiratory Failure / Sodium Nitroprusside1
2CompletedTreatmentArterial Hypotension1
2CompletedTreatmentCerebral Oxygenation1
2CompletedTreatmentHypertensive1
2CompletedTreatmentSchizophrenic Disorders1
2RecruitingPreventionStress Disorders, Post-Traumatic1
2RecruitingTreatmentDepressive State1
2RecruitingTreatmentSchizophrenic Disorders1
2TerminatedDiagnosticHyperlipidemias1
2, 3CompletedTreatmentMyocardial Infarction (MI)1
3CompletedTreatmentHeart Failure, Unspecified / Hypertensive1
3CompletedTreatmentHypertensive1
4Not Yet RecruitingTreatmentAcute Heart Failure (AHF)1
4TerminatedPreventionMyocardial Infarction (MI)1
4Unknown StatusDiagnosticHealthy Volunteers1
4Unknown StatusScreeningNitroprusside / Thyroid Hormones1
Not AvailableCompletedNot AvailableCancers / Endothelial Dysfunction / Hypertensive1
Not AvailableCompletedNot AvailableHypotension, Controlled1
Not AvailableCompletedNot AvailableIntracerebral Hemorrhage / Subarachnoid Hemorrhage1
Not AvailableCompletedBasic ScienceHeart Diseases / Heart Failure, Unspecified / Vasodilatation1
Not AvailableCompletedBasic ScienceHeart Diseases / Vasodilation1
Not AvailableCompletedTreatmentCVA (Cerebrovascular Accident) / Intracerebral Hemorrhage / Intracranial Hemorrhages1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1
Not AvailableRecruitingNot AvailableLeiomyomas1
Not AvailableTerminatedBasic ScienceProphylaxis of cardiomyopathy / Stress-induced (Takotsubo) Cardiomyopathy1
Not AvailableUnknown StatusNot AvailableDiabetes Mellitus (DM)1

Pharmacoeconomics

Manufacturers
  • Hoffmann la roche inc
  • Abbott laboratories
  • Abbott laboratories pharmaceutical products div
  • Hospira inc
  • Abraxis pharmaceutical products
  • Baxter healthcare corp anesthesia and critical care
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionIntravenous50 mg
Injection, solutionIntravenous.5 mg/mL
Injection, solution, concentrateIntravenous50 mg/2mL
InjectionIntravenous25 mg/mL
Injection, solution, concentrateIntravenous25 mg/mL
SolutionIntravenous25 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP0.071ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area148.38 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity39.44 m3·mol-1ChemAxon
Polarizability16.52 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8308
Blood Brain Barrier+0.9314
Caco-2 permeable-0.5269
P-glycoprotein substrateNon-substrate0.8966
P-glycoprotein inhibitor INon-inhibitor0.919
P-glycoprotein inhibitor IINon-inhibitor0.9767
Renal organic cation transporterNon-inhibitor0.9109
CYP450 2C9 substrateNon-substrate0.8573
CYP450 2D6 substrateNon-substrate0.8353
CYP450 3A4 substrateNon-substrate0.6675
CYP450 1A2 substrateNon-inhibitor0.6719
CYP450 2C9 inhibitorNon-inhibitor0.8599
CYP450 2D6 inhibitorNon-inhibitor0.9186
CYP450 2C19 inhibitorNon-inhibitor0.8218
CYP450 3A4 inhibitorNon-inhibitor0.9763
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9583
Ames testNon AMES toxic0.5204
CarcinogenicityCarcinogens 0.6595
BiodegradationNot ready biodegradable0.5759
Rat acute toxicity2.9543 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9345
hERG inhibition (predictor II)Non-inhibitor0.9596
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as organic transition metal salts. These are organic salt compounds containing a transition metal atom in its ionic form.
Kingdom
Organic compounds
Super Class
Organic salts
Class
Organic metal salts
Sub Class
Organic transition metal salts
Direct Parent
Organic transition metal salts
Alternative Parents
Organotransition metal compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Organic anions
Substituents
Organic transition metal salt / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative / Organonitrogen compound / Organometallic compound / Organic transition metal moeity / Organic anion
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
iron coordination entity (CHEBI:7596)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein kinase activity
Specific Function
Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate ...
Gene Name
NPR1
Uniprot ID
P16066
Uniprot Name
Atrial natriuretic peptide receptor 1
Molecular Weight
118918.11 Da
References
  1. Fortin Y, De Lean A: Role of cyclic GMP and calcineurin in homologous and heterologous desensitization of natriuretic peptide receptor-A. Can J Physiol Pharmacol. 2006 May;84(5):539-46. [PubMed:16902599]
  2. Madhani M, Okorie M, Hobbs AJ, MacAllister RJ: Reciprocal regulation of human soluble and particulate guanylate cyclases in vivo. Br J Pharmacol. 2006 Nov;149(6):797-801. Epub 2006 Oct 3. [PubMed:17016498]
  3. Steinmetz M, Potthast R, Sabrane K, Kuhn M: Diverging vasorelaxing effects of C-type natriuretic peptide in renal resistance arteries and aortas of GC-A-deficient mice. Regul Pept. 2004 Jun 15;119(1-2):31-7. [PubMed:15093694]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:35